Hong Zhou

Hong Zhou

Auto-generated profile, based on publicly available information

Hong Zhou

Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 201610, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
QYQianqian Yin
Qianqian Yin
LSLibo Sun
Libo Sun
XCXiaojie Cai
Xiaojie Cai
FLFangzhou Lou
Fangzhou Lou
YSYang Sun
Yang Sun
HWHonglin Wang
Honglin Wang

28 March 2022 in EMBO Reports
Verified
Journal Article
Closed access
HZHong Zhou
Hong Zhou
FLFangzhou Lou
Fangzhou Lou
JBJing Bai
Jing Bai
YSYang Sun
Yang Sun
WCWei Cai
Wei Cai
HWHonglin Wang
Honglin Wang

30 January 2024 in EMBO Reports
Verified
Journal Article
Open access
STSibei Tang
Sibei Tang
JZJunxun Zhang
Junxun Zhang
FLFangzhou Lou
Fangzhou Lou
HZHong Zhou
Hong Zhou
XCXiaojie Cai
Xiaojie Cai
HWHonglin Wang
Honglin Wang
Micropeptides encoded by short open reading frames (sORFs) within long noncoding RNAs (lncRNAs) are beginning to be discovered and characterized as regulators of biological and pathological processes. Here, we find that lncRNA Dleu2 encodes a 17-amino-acid micropeptide, which we name Dleu2-17aa, that is abundantly expressed in T cells. Dleu2-17aa promotes inducible regulatory T (iTreg) cell generation by interacting with SMAD Family Member 3 (Smad3) and enhancing its binding to the Foxp3 conserved non-coding DNA sequence 1 (CNS1) region. Importantly, the genetic deletion of Dleu2-17aa in mice by start codon mutation impairs iTreg generation and worsens experimental autoimmune encephalomyelitis (EAE). Conversely, the exogenous supplementation of Dleu2-17aa relieves EAE. Our findings demonstrate an indispensable role of Dleu2-17aa in maintaining immune homeostasis and suggest therapeutic applications for this peptide in treating autoimmune diseases.

1 March 2021 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
LCLinjiao Chen
Linjiao Chen
JBJing Bai
Jing Bai
DPDanhong Peng
Danhong Peng
YGYuanyuan Gao
Yuanyuan Gao
XCXiaojie Cai
Xiaojie Cai
HWHonglin Wang
Honglin Wang
IL-17–secreting Th17 cells play an important role in the pathogenesis of various inflammatory and autoimmune diseases. IL-17–targeted biologics and small molecules are becoming promising treatments for these diseases. In this study, we report that SZB120, a derivative of the natural compound 3-acetyl-β-boswellic acid, inhibits murine Th17 cell differentiation by interacting with the α-subunit of eukaryotic initiation factor 2 (eIF2α). We showed that SZB120 directly interacts with eIF2α and contributes to serine 51 phosphorylation of eIF2α. The suppressive effect of SZB120 on Th17 cell differentiation was reversed by GSK2606414, an inhibitor of eIF2α phosphokinase. Phosphorylation of eIF2α induced by SZB120 decreased the protein expression of IκBζ, which is important for Th17 cell differentiation. Notably, interaction with eIF2α by SZB120 also impaired glucose uptake and glycolysis in T cells. In vivo, SZB120 treatment of C57BL/6 mice significantly attenuated IL-17/Th17–mediated autoimmune disease. Our study indicates that SZB120 is a promising drug candidate for IL-17/Th17–mediated inflammatory diseases.